IDH3A Inhibitors

IDH3A inhibitors belong to a chemical class of compounds designed to target and inhibit the isocitrate dehydrogenase 3A (IDH3A) enzyme. These inhibitors are primarily developed for their potential utility in the field of cancer research, particularly in addressing malignancies associated with mutations in the IDH3A enzyme. The IDH3A enzyme is a crucial component of the tricarboxylic acid (TCA) cycle, a metabolic pathway that plays a fundamental role in energy production and biosynthesis within cells. Specifically, IDH3A catalyzes the conversion of isocitrate to alpha-ketoglutarate (α-KG), a key intermediate metabolite in the TCA cycle.

IDH3A inhibitors are designed to interfere with the enzymatic activity of IDH3A, disrupting the normal flow of the TCA cycle. In cancer, mutations in the IDH3A gene can lead to a gain-of-function alteration in the enzyme's activity. This altered IDH3A produces an oncometabolite called D-2-hydroxyglutarate (D-2-HG), which is not found in normal cells. Accumulation of D-2-HG can have profound effects on cellular metabolism and gene regulation, contributing to the development and progression of cancer. IDH3A inhibitors are engineered to specifically target and inhibit the mutant IDH3A enzyme, thus reducing the aberrant production of D-2-HG.